Abstract
Lamotrigine (LTG) was added to other antiepileptic drugs (AEDs) in a study of adjunctive therapy. In addition to seizure control and adverse effects, patients were evaluated for changes in mood states and quality of life. The Profile of Mood States (POMS) and 31-item Quality of Life in Epilepsy (QOLIE-31) instruments were administered at baseline (N=196), after addition of LTG as adjunctive treatment (N=155), and after withdrawal of other drugs to LTG monotherapy (N=51). POMS scores correlated highly with the QOLIE-31 Emotional Well-Being subscale, a known measure of mood. All POMS subscales were significantly improved (all P<0.0001) at the end of the adjunctive therapy phase. POMS scores remained significantly better than baseline among patients completing the conversion to monotherapy (all P<0.003). Minimal clinically important changes were determined for POMS scores. These data indicate that LTG improves mood states to a clinically important degree, even in the presence of other AEDs. The improvement likely was not a synergy but attributable only to LTG because it remained stable after withdrawal of the other AEDs.
References
Apr 11, 1992·Medical Care·B G VickreyR H Brook
Mar 1, 1989·Medical Care·L E KazisR F Meenan
Jan 1, 1987·Journal of Chronic Diseases·G GuyattG Norman
Oct 1, 1970·Journal of Educational Psychology·E Gaudry, C D Spielberger
Oct 1, 1995·Archives of Neurology·K PerrineO Devinsky
Nov 1, 1995·Epilepsia·O DevinskyR D Hays
Sep 1, 1993·Epilepsy Research·G A BakerD W Chadwick
Dec 1, 1993·Neurology·C B DodrillN M Sussman
Jan 1, 1994·Archives of General Psychiatry·R C KesslerK S Kendler
Mar 1, 1993·Epilepsia·D SmithD W Chadwick
Jan 1, 1997·The Journal of Clinical Psychiatry·D Blumer
May 13, 1998·Epilepsia·J A CramerB Hermann
Apr 1, 1999·Journal of Clinical Psychology·D L NyenhuisA Parmentier
Apr 11, 2000·Epilepsia·V PulliainenH Kalska
Jul 18, 2000·Epilepsia·J A CramerJ J Cereghino
Jun 26, 2001·Epilepsia·R MartinF Gilliam
Mar 21, 2002·Epilepsy Research·Joyce A CramerAnn Jacoby
Jun 1, 1961·Archives of General Psychiatry·A T BECKJ ERBAUGH
Nov 26, 2003·Epilepsia·Joyce A CramerUNKNOWN Epilepsy Impact Project Group
May 5, 2004·Epilepsy & Behavior : E&B·Joyce A CramerRobert P Kustra
Citations
Aug 22, 2013·Journal of Medical Internet Research·Urs-Vito AlbrechtUte von Jan
Apr 26, 2011·Epilepsy & Behavior : E&B·Hiroko KatoKousuke Kanemoto
Oct 1, 2010·Epilepsy & Behavior : E&B·X WenA G Hartzema
Oct 27, 2009·Epilepsy & Behavior : E&B·Melanie GalantiZachary N Stowe
Jan 30, 2007·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·B ClemensK Hollódy
Dec 15, 2006·Epilepsy & Behavior : E&B·Toufic A FakhouryAlain Vuong
Oct 31, 2006·Epilepsy & Behavior : E&B·Alan B EttingerAnne E Hammer
Sep 20, 2012·Epilepsia·Hsin-Yi HuangFu-Zen Shaw
Dec 27, 2005·Epilepsy & Behavior : E&B·Mary Ann WerzPaula Ogrocki
Aug 2, 2005·Epilepsy & Behavior : E&B·Felipe FregniAlvaro Pascual-Leone
Feb 25, 2014·The Tohoku Journal of Experimental Medicine·Yasuhiro MoriSunao Kaneko
Jun 4, 2016·Pharmacological Reviews·Martin J BrodieBernhard J Steinhoff
Aug 12, 2006·Journal of Child Neurology·Raj D Sheth, Barry E Gidal
Jun 18, 2017·Epilepsy & Behavior : E&B·Luba NakhutinaArthur C Grant
Jan 27, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Vladimir V Kalinin
Oct 25, 2008·Drugs & Aging·Toufic A FakhouryAlain Vuong
Feb 10, 2006·Expert Review of Neurotherapeutics·Steven C Schachter
Sep 25, 2017·Frontiers in Psychology·Alessandro QuartiroliGerard J Fogarty
Mar 8, 2012·CNS Drugs·John PiedadAndrea E Cavanna
Jul 17, 2008·Drugs·J Mitchell MillerJohn A Messenheimer